Troy Edward Wilson bought $410K of Kura Oncology (KURA)
Executed Sep 8 2025, disclosed Sep 9 2025, 1 day later.
Over the 21 trading sessions from the disclosed entry session (Sep 9 2025), the stock returned +15.8% (delay-adjusted); from the execution session (Sep 8 2025), +19.1%. Derived: entry at the session's open, exit at the close 20 sessions later.
Troy Edward Wilson (President and CEO) filed 2 Form 4 reports in the trailing twelve months (2 purchases, 0 sales), most often in Kura Oncology, Inc. (KURA). Across 2 priced purchase filings, the average 21-session return was +1.5% from execution and +1.5% from disclosure (delay-adjusted; derived). The largest single filing was $1.2M of KURA (100,000 sh × $12.39, as filed), executed Aug 24.
Healthcare · Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer
More Healthcare filings→ Insider filings, newest first→ View the original filing at www.sec.gov→100,000 sh × $12.39
Exec Aug 24
Filed Aug 24 · 5:30 PM ET KURAPURCHASE Kura Oncology, Inc. $1.1M
100,000 sh × $11.12
Exec Aug 17
Filed Aug 17 · 4:45 PM ET KURASALE Kura Oncology, Inc. $327K
36,615 sh × $8.94
Exec Sep 29 2025
Filed Sep 29 2025 · 5:30 PM ET KURAPURCHASE Kura Oncology, Inc. $214K
36,506 sh × $5.85
Exec Aug 12 2025
Filed Aug 14 2025 · 4:05 PM ET